Skip to content

Erasca, Inc. ERAS Accounts Payable

Accounts Payable at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$4.23B+5.8%
Eli Lilly logo
Eli LillyLLY
$5.03B+46.1%
Pfizer logo
PfizerPFE
$4.51B-14.0%
Amgen logo
AmgenAMGN
$2.94B+22.0%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$80.54M+69.5%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$20.74M+17.6%

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$4.69B+1,196%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Reported directly by Erasca, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.

The official record: Erasca, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Erasca, Inc.'s accounts payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Erasca, Inc.'s accounts payable?
Erasca, Inc. (ERAS) reported accounts payable of $2.16M in Q1 2026.
How has Erasca, Inc.'s accounts payable changed year-over-year?
Erasca, Inc.'s accounts payable decreased by 4.4% year-over-year, from $2.26M to $2.16M.
What is the long-term trend for Erasca, Inc.'s accounts payable?
Over 4 years (2021 to 2025), Erasca, Inc.'s accounts payable has grown at a 0.8% compound annual growth rate (CAGR), from $7.68M to $7.94M.
What does accounts payable mean?
Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.